New drug ATG-022 enters human testing for Hard-to-Treat cancers
NCT ID NCT05718895
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called ATG-022 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Up to 156 participants will receive the drug every three weeks, and researchers will also watch for any signs that the tumors shrink or stop growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ATG-022 (a drug given by IV every 3 weeks)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 156 participants, focused on finding a safe dose. It is too soon to know if ATG-022 will shrink tumors or improve survival, and there may be side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Anhui Provincial Hospital
RECRUITINGHefei, China
Contact Email: •••••@•••••
Contact
-
Beijing GoBroad Hospital
RECRUITINGBeijing, China
Contact Email: •••••@•••••
Contact
-
Cabrini Health Limited
RECRUITINGMalvern, Australia
Contact Email: •••••@•••••
Contact
-
Cancer Research SA Pty Ltd
COMPLETEDAdelaide, Australia
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Email: •••••@•••••
Contact
-
Fujian Cancer Hospital
RECRUITINGFuzhou, China
Contact
Contact Email: •••••@•••••
Contact
-
Gansu provincial cancer hospital [recruiting]
RECRUITINGLanzhou, China
Contact Email: •••••@•••••
Contact
-
General Hospital of Ningxia Medical University
RECRUITINGYinchuan, China
Contact Email: •••••@•••••
Contact
-
Hubei Cancer Hospital
RECRUITINGWuhan, China
Contact Email: •••••@•••••
Contact
-
Integrated Clinical Oncology Network Pty Ltd (Icon)
RECRUITINGSouth Brisbane, Australia
Contact
Contact Email: •••••@•••••
-
Jinan Central Hospital
RECRUITINGJinan, China
Contact Email: •••••@•••••
Contact
-
Liaoning Cancer Hospital
RECRUITINGShenyang, China
Contact Email: •••••@•••••
Contact
-
Shanxi provincial cancer hospital
RECRUITINGTaiyuan, China
Contact Email: •••••@•••••
Contact
-
The Affiliated Hospital of Qingdao University
RECRUITINGQingdao, China
Contact Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
Contact Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Zhenghzou University
RECRUITINGZhengzhou, China
Contact Email: •••••@•••••
Contact
-
The First affiliated hospital of Xi'An Jiao Tong Ubiversity
RECRUITINGXi'an, China
Contact Email: •••••@•••••
Contact
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiangzhuang, China
Contact Email: •••••@•••••
Contact
-
Tianjin Medical Universuty Cancer Institute & Hospital
RECRUITINGTianjin, China
Contact Email: •••••@•••••
Contact
-
Tongren Hospital Shanghai
RECRUITINGShanghai, China
Contact Email: •••••@•••••
Contact
-
West China Hospital, Sichuan University
RECRUITINGChengdu, China
Contact
Contact Email: •••••@•••••
Contact
-
Xuzhou Central Hospital
RECRUITINGXuzhou, China
Contact Email: •••••@•••••
Contact